Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bullish +72

Moderna Stock Surges As Federal Health Regulators Clear Milestone Older Adult Flu Vaccine Data - TIKR.com

📈 Moderna stock surges for a fifth straight day after FDA staff reviewers publish briefing documents suggesting mFlusiva flu shot data supports effectiveness in adults 65 and older.

🔄 The FDA reversed its initial rejection of the flu vaccine application after Moderna agreed to amend its trial design regarding the control arm for patients 65 and over.

🗓️ An independent advisory panel will vote on mFlusiva benefits versus risks for adults 50 and older, with a final FDA decision expected by August 5.

💉 If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States.

📊 Jefferies analyst Andrew Tsai projects $750 million in combined U.S. flu and COVID-flu combo vaccine sales by 2030.

⚠️ FDA staff noted limitations including study during only one flu season and exclusion of immunocompromised or very frail older adults from trials.

🔬 Moderna agreed to run an additional study in the 65-plus age group if approval is granted for that population.

🌍 The company recently received EU approval for mCOMBRIAX, its flu-plus-COVID combination vaccine, marking the first of its kind globally.

👩‍💼 Moderna appointed Ester Banque as new Chief Commercial Officer to lead upcoming product launches globally.

🚀 Investors are optimistic about a multi-product future with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.

Bullish Signals
  • Moderna stock has gained meaningfully over five trading sessions following the publication of FDA briefing documents that suggest a favorable review of its mFlusiva flu vaccine.
  • The FDA reversed its initial rejection of the flu vaccine application after Moderna amended its trial design, signaling a positive shift in regulatory stance.
  • Approval of mFlusiva would establish it as the first mRNA-based seasonal flu vaccine in the United States, creating a unique market position.
  • Analyst Andrew Tsai from Jefferies projects $750 million in combined U.S. sales for flu and COVID-flu combo vaccines by 2030.
  • Moderna recently secured EU approval for mCOMBRIAX, becoming the first company globally to receive approval for a flu-plus-COVID combination vaccine.
  • The appointment of Ester Banque as Chief Commercial Officer strengthens the company's leadership team for upcoming global product launches.
  • Future pivotal data readouts for cancer therapy Intismeran and rare disease programs are expected in 2026, suggesting a robust pipeline beyond vaccines.
Risk Factors
  • The mFlusiva vaccine has only been studied during one flu season, which may limit the generalizability of its effectiveness data.
  • Immunocompromised and very frail older adults were excluded from the trials for mFlusiva, leaving efficacy in these high-risk groups unproven.
  • The FDA briefing documents explicitly note limitations regarding the trial design and patient population included in the current data.
Full Analysis
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had previously rejected the application due to concerns about trial design, specifically the lack of a preferred higher-dose control arm for the elderly population. The company successfully amended its application to address these initial concerns, leading to a favorable tone in the latest briefing documents ahead of an independent advisory panel meeting scheduled for Thursday. The panel will vote on whether mFlusiva's benefits outweigh risks for adults 50 and older, with a final FDA decision expected by August 5. If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States. Despite some noted limitations, such as the vaccine being studied during only one flu season and the exclusion of immunocompromised or very frail older adults from trials, Moderna has agreed to conduct an additional study in the 65-plus age group if approval is granted for that specific population. Analyst Andrew Tsai from Jefferies views the assessment positively, projecting combined U.S. sales of $750 million for flu and COVID-flu combo vaccines by 2030. Beyond the flu vaccine milestone, Moderna is gaining momentum with recent EU approval for mCOMBRIAX, its first-of-its-kind flu-plus-COVID combination vaccine globally. The company also appointed Ester Banque as Chief Commercial Officer to lead upcoming product launches. Investors are increasingly optimistic about a multi-product future, with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.